Skip to main content

Marinus Pharmaceuticals, Inc. (MRNS)

NASDAQ: MRNS · IEX Real-Time Price · USD
11.08 0.37 (3.45%)
Dec 8, 2021 4:00 PM EST - Market closed
Market Cap407.42M
Revenue (ttm)15.37M
Net Income (ttm)-87.94M
Shares Out36.77M
EPS (ttm)-2.48
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume90,440
Open10.84
Previous Close10.71
Day's Range10.42 - 11.19
52-Week Range9.10 - 20.04
Beta1.15
AnalystsStrong Buy
Price Target30.11 (+171.8%)
Earnings DateNov 9, 2021

About MRNS

Marinus Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing and commercializing therapeutics to treat rare seizure disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in formulations for two routes, including intravenous (IV) and oral for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ganaxolone product candidate, acts at synaptic and extrasynaptic GABAA receptors, a target fo...

IndustryPharmaceuticals
IPO DateJul 31, 2014
Employees100
Stock ExchangeNASDAQ
Ticker SymbolMRNS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for MRNS stock is "Strong Buy." The 12-month stock price forecast is 30.11, which is an increase of 171.75% from the latest price.

Price Target
$30.11
(171.75% upside)
Analyst Consensus: Strong Buy

News

Marinus Pharmaceuticals Announces New Clinical and Research Data to be Presented at American Epilepsy Society Meeting

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Announces New Clinical and Research Data to be Presented at American Epilepsy Society Meeting

5 days ago - Business Wire

Marinus Pharmaceuticals Announces Nine Presentations and Virtual Investor Event at American Epilepsy Society 2021 Ann...

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Announces Nine Presentations and Virtual Investor Event at American Epilepsy Society 2021 Annual Meeting

2 weeks ago - Business Wire

Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences

3 weeks ago - Business Wire

Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Tops Revenue Estimates

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 30.26% and 335.95%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the st...

4 weeks ago - Zacks Investment Research

Recap: Marinus Pharmaceuticals Q3 Earnings

Marinus Pharmaceuticals (NASDAQ:MRNS) reported its Q3 earnings results on Tuesday, November 9, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

4 weeks ago - Benzinga

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financial Results

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #Earnings--Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financial Results

4 weeks ago - Business Wire

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--MARINUS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

1 month ago - Business Wire

Marinus Pharmaceuticals to Provide Business Update and Announce Third Quarter 2021 Financial Results on November 9, 2021

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals to Provide Business Update and Announce Third Quarter 2021 Financial Results on November 9, 2021

1 month ago - Business Wire

Marinus Pharmaceuticals Joins the Loulou Foundation in Collaboration on CANDID, a Comprehensive Observational Study i...

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Joins the Loulou Foundation in Collaboration on CANDID, a Comprehensive Observational Study in CDKL5 Deficiency Disorder

1 month ago - Business Wire

Marinus Pharmaceuticals Provides Strategic Update at Virtual R&D Event

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Provides Strategic Update at Virtual R&D Event

2 months ago - Business Wire

Marinus Pharmaceuticals Announces Virtual R&D Event on October 5, 2021

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Announces Virtual R&D Event on October 5, 2021

2 months ago - Business Wire

Marinus Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of New Drug Application for Ganaxolon...

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of New Drug Application for Ganaxolone in CDKL5 Deficiency Disorder

2 months ago - Business Wire

European Medicines Agency Grants Marinus Pharmaceuticals Accelerated Assessment of Ganaxolone for Treatment of CDKL5 ...

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--European Medicines Agency Grants Marinus Pharmaceuticals Accelerated Assessment of Ganaxolone for Treatment of CDKL5 Deficiency Disorder.

3 months ago - Business Wire

Marinus Pharmaceuticals Reports Topline Ganaxolone Phase 2 Open-Label Results in Tuberous Sclerosis Complex and Recei...

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Reports Topline Ganaxolone Phase 2 Open-Label Results in Tuberous Sclerosis Complex and Receives FDA Orphan Drug Designation

3 months ago - Business Wire

Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Lags Revenue Estimates

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 4.41% and -25.96%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Marinus Pharmaceuticals: Q2 Earnings Insights

Shares of Marinus Pharmaceuticals (NASDAQ:MRNS) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share fell 306.25% over the past year to ($0.65), which beat the esti...

3 months ago - Benzinga

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #Earnings--Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results

3 months ago - Business Wire

Marinus Pharmaceuticals to Provide Business Update and Announce Second Quarter 2021 Financial Results on August 10, 2021

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals to Provide Business Update and Announce Second Quarter 2021 Financial Results on August 10, 2021

4 months ago - Business Wire

Marinus Files US Application For Ganaxolone For Genetic Epilepsy, Inks European Commercialization Pact With Orion

Marinus Pharmaceuticals Inc (NASDAQ: MRNS) has submitted a marketing application to the FDA seeking approval for its lead product candidate, ganaxolone, to treat seizures associated with CDKL5 deficienc...

4 months ago - Benzinga

Marinus Pharmaceuticals Announces Exclusive Collaboration with Orion Corporation for European Commercialization of Ga...

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Announces Exclusive Collaboration with Orion Corporation for European Commercialization of Ganaxolone

4 months ago - Business Wire

Marinus Pharmaceuticals Submits New Drug Application (NDA) to FDA for Ganaxolone for the Treatment of Seizures Associ...

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Submits New Drug Application to FDA for Ganaxolone for the Treatment of Seizures Associated with CDKL5 Deficiency Disorder

4 months ago - Business Wire

New Strong Sell Stocks for July 16th

JAZZ, MRNS, TWO, NCMI, and CRON have been added to the Zacks Rank #5 (Strong Sell) List on July 16, 2021

Other symbols:CRONJAZZNCMITWO
4 months ago - Zacks Investment Research

New Strong Sell Stocks for July 9th

BEST, JRSH, MRNS, MFGP and SABR have been added to the Zacks Rank #5 (Strong Sell) List on July 9, 2021.

Other symbols:BESTJRSHMFGPSABR
4 months ago - Zacks Investment Research

Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Santiago Arroyo, M.D., Ph.D.

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Santiago Arroyo, M.D., Ph.D.

5 months ago - Business Wire

New Strong Sell Stocks for June 21st

ASTE, CMTL, EBMT, MRNS and WRE have been added to the Zacks Rank #5 (Strong Sell) List on June 21, 2021.

Other symbols:ASTECMTLEBMTWRE
5 months ago - Zacks Investment Research